Previous data showed that Erianin has a broad-spectrum anti-tumor effect, including regulating signaling pathways such as PI3K/AKT (Xu et al., 2021; Zhang et al., 2021), REST/LRSAM1 (Mansuer et al., 2024), NRF2 (Xiang et al., 2021), and MEK1/2 (Zhu et al., 2025), etc. These mechanisms inhibit the proliferation across multiple cancer types, such as lung, colon, breast, and pancreatic cancer, and prevent the occurrence and progress of tumors. This evidence concerns the gene REST and cancer.